University of Miami Miami Valves 2025

1. Overview

The University of Miami Miami Valves 2025 is a premier structural heart disease conference focusing on the latest innovations in transcatheter valve therapies. The course provides a deep dive into TAVR, TMVR, and tricuspid interventions, alongside cutting-edge research on AI integration and novel device clinical trials.

Course Date: 2025

2. Learning Objectives

• Evaluate recent clinical trial data for TAVR, including the PROPEL and EASY II trials.

• Discuss the management of complex aortic valve cases, such as bicuspid anatomy and chronic aortic regurgitation.

• Analyze emerging technologies for mitral valve repair and replacement, focusing on TEER durability and neo-LVOT simulation.

• Review FDA-approved and investigational therapies for tricuspid regurgitation, including replacement and edge-to-edge repair.

• Implement novel techniques for structural interventions, including PFO closure in older adults and management of paravalvular leaks.

3. Target Audience

4. Topics

1. What Did We Learn from TAVR UNLOAD

2. Selected Case of CE Approved TAVR Valve – Acurate Neo2

3. Hybrid TAVR

4. Septal Occulders- Not Just for the Intra-Atrial Septum

5. Novel Vascular Closure Device (xDot) – First in Human Experience

6. AI for Cardiovascular Staff Support

7. Novel RV Restoration System

8. Novel TMVR Devices

9. Latest Clinical Update – Silara MiBridge. Direct Annuloplasty System

10. Novel Transcatheter Mitral Annuloplasty Repair. Technology and Pre-Clinical Experience

11. EASY II Trial – Pioneering Temporary A-V Sequential Pacing for Enhanced Cardiac Care

12. Novel Device for Pulmonic Valve – Alterra

13. Tricuspid Valve Replacement in a Patient with a Torn Leaflet

14. Understanding the Tricuspid Regurgitation (Pathologist Perspective)

15. Multi Modality Imaging of Tricuspid Valve

16. Surgical Treatment of Tricuspid Valve

17. FDA Approved Edge to Edge Repair of Tricuspid (What We Know)

18. FDA Approved Tricuspid Valve Replacement – What We Know

19. TTVR with the Evoque Valve via the Transjugular Approach

20. Expanding Indications for PFO Closure Patients ≥ 60-Years Old

21. A Case of Severe Bioprosthetic Valve Dysfunction

22. Neo-LVOT Simulations for TMVR

23. Preventing LVOT Obstruction During TMVR – Septal Reduction and LAMPOON – What We Know

24. TMVR and the Tendyne Roll-In and MAC Experience

25. APOLLO Trial MAC Cohort

26. Investigational Transeptal TMVR – SAPIEN M3

27. ViMAC with SUPERMAN

28. Imaging to Plan Mitral Valve Procedures

29. Durability of Edge-to-Edge Repair

30. TEER in Moderate MR

31. Recurrent Heart Failure after M-TEER – More than the Mitral Valve

32. Clinical Trials for Mitral Regurgitation Beyond TEER – Where to Next

33. Progress in Mitral Valve Replacement

34. LAVA-ECMO for Cardiogenic Shock and Acute Aortic Regurgitation as a Bridge to Valve Replacement

35. Pathological Insights to the Native Aortic Valve Regurgitation

36. Dedicated TAVR Devices for Chronic Aortic Regurgitation

37. Single Center Results for a Balloon Expandable Valve in Native Valve AI

38. Where Are We with TAVR for Bicuspid

39. AI Simulation Assisted TAVR

40. A Case of Bicuspid TAVR with AI Planning

41. TAVR 2025 – The Begins….

42. TAVR US Origin

43. Clinical Trial Propel TAVR Forward – Building the Evidence Base for Low Surgical Risk Patients

44. Late PVL After BE THV

45. Transcatheter Management of Failed Ross Procedure

46. Short Term ACS Post TAVR

47. On the Shoulders of Our Mentors… How to Maximize Your Career Development Pathway

48. Left Atrium to Coronary Sinus Shunting – Edwards’ APTURE Shunt and ALT-FLOW II Trial

49. Transcatheter Treatment of a Sinus Venous ASD with Partial Anomalous Pulmonary Venous Return

50. Percutaneous Tricuspid Valve Intervention(s)

51. Percutaneous Stenting of Severe LVAD Outflow Graft Obstruction